沈阳三生制药有限责任公司 S BIO.PHARM.GROUP I
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced 2023-08-25 10:06
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% 2023-03-22 11:15
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital 2022-01-29 11:37
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development 2021-08-26 22:09
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth 2021-03-31 09:11
Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration 2020-12-14 22:28
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212 2020-11-23 21:28
3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry 2020-09-02 02:15
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2% 2020-03-31 12:29
3SBIO makes investment in MPM's $100M Oncology Innovations Fund and donation to Dana-Farber cancer research 2020-03-01 16:30
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration 2019-11-18 08:30
3SBio's MSCI ESG Rating Upgraded to BBB, Ranking at the Forefront of the Global Biotechnology Industry 2019-09-11 16:52
Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution 2019-07-29 21:42
3SBio Unveils 2018 Annual Results: Revenue Soars by 22.7%, Normalized Net Profit Soars by 29.0%, R&D Expenses Jumps Over 40% 2019-03-21 00:14
3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China 2019-03-04 07:00
3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies 2019-02-11 20:19
3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies 2019-02-11 20:18
3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5% 2018-03-26 22:09
China FDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Patients with Type-2 Diabetes 2018-01-04 14:46
3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure 2017-09-03 21:01
1